Jiangsu Tianqin Investment

Jiangsu Tianqin Investment, primarily operating through its subsidiary Jiangsu Tianqin Pharmaceutical Technology, is a leading Chinese Contract Research Organization (CRO) specializing in non-clinical safety evaluation and drug research. The company is distinguished by its extensive expertise and infrastructure for non-human primate (NHP) research, maintaining large-scale breeding and experimental facilities to support global drug development. Tianqin provides a comprehensive suite of services including toxicology, pharmacokinetics, safety pharmacology, and efficacy evaluation for small molecules, biologics, and advanced therapies. It holds key certifications such as NMPA GLP and AAALAC accreditation, ensuring high standards of animal welfare and regulatory compliance. By offering specialized NHP-based research, the company serves as a critical partner for pharmaceutical and biotechnology firms in their preclinical pipelines. Its integrated approach helps clients navigate the complexities of the preclinical phase and accelerate the transition of drug candidates into clinical trials.